Overall, the majority of previous cancer studies have consistently demonstrated significant downregulation of the PER gene family, often linked to reduced patient survival, poorer prognosis, and clinicopathological factors such as low tumor differentiation, advanced tumor stage, lymph node metastasis, and more aggressive tumor characteristics. This evidence concerns the gene PER1 and neoplasm.